UK markets closed

Inari Medical, Inc. (NARI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
67.08+1.50 (+2.29%)
At close: 04:00PM EDT
70.43 +3.35 (+4.99%)
After hours: 06:45PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    I did a search on "DVT" and went onto sites within the first number of pages of search results that were obvious hospital systems (approximately 30 sites) that went into details of DVT treatments, including Cedar-Sinai, George Washington, Mayo, Hopkins, Penn, Stanford, Inova, UCDavis, UofM, Northwestern, UPMC, Cleveland Clinic and a number of others, even onto sites that were medically related like the CDC, WebMD, NHS and NIH (even Wikipedia). Of all the sites, ONLY A SINGLE ONE mentioned a mechanical thrombectomy as a treatment (Penn) and Wikipedia had a one-liner, recommended "in rare cases".

    What I'm getting at:
    - NARI has a lot to do in getting their customers to get the word out and even mention the procedure and gain traction in the treatment of DVT.
    - NARI seems to have made huge strides, despite it not being a mainstream treatment
    - NARI marketing s7cks... should hire a digital marketer, someone that copies, modifies and suggests customer webpages allowing the publishing of a new page easier instead of relying and waiting for someone else to do it; someone to modify and submit edits to the medical information providers on the internet.
  • A
    amazing, blew it out of the water.

    - revenue 144% over last year
    - 2x forecast for this year
    - earnings crossed over to positive
    - huge margins
    + entering new European market
    + 2 new products

    I think we'll see $199 before the end of the year
  • A
    I'm wondering if the "fantastic position we're going to be in post-COVID" is leaking...
  • M
    wasn't expecting it to open at double the price but that's fine. this company sells 2 very successful products and they have HUGE demands for them. worth the 45 a stock buy in. it will be over 300 in 5 years.
  • D
    There is 50 M outstanding shares, so 2 M is not much of dilution.
    They are profitable, they have 179 M cash and only 29 M debt.
    Why this offering, they do not need money? It could be some acquisition.
    Any second offering with intention to grow business is a wise decision.
  • A
    what i got out of the call:
    procedure is super safe, super effective above anything else.
    replenishment product pipeline seems stable and established, increased due to new product introductions.
    european foothold established, especially in western europe.
    a pipeline of tangential new products can be expected to be released Q4 through the 1H of next year, in addition to flowsaver.
    TAM related to Covid induced clots was 11% in Q2 and decreasing from Q1, down to 4% recently, yet total TAM increased...
    which means (unfortunately) the significant Q3 spike we're seeing in Covid now is going to be on top of the increase in "normal"/target (non-Covid) procedures.
  • s

    This company must have multi-billion dollar product. MC=1.7 billion...

    Talk about potential for growth...

    Good Luck and do your due diligence always...
  • A
    any news to account for a 12% drop?
  • K
    K B B
    You bet the high valuation is justified !!!

    113% yoy revenue growth ... beats both top and bottom line ... 13c vs 5c and 57.4M vs 55M revs ... cash increased from $164M to $174M.

    Full year guidance increased from 234M to 245M.
  • A
    So, the company hit their target and has great prospects, of course the stock tanks? Do I not understand what this whole thing is about anymore?
  • s
    For those who are uninitiated with IPOs...

    Usual IPO only issue 10-20% of company and then there is lock out period of 3-6 months where no insiders can sell. In about a year 50-80% will be floated with secondary from the company once IPO is successful. Secondary is better since large institutions will be interested in buying large shares of stock. In most cases, they just sell it open market to get float up to 80%...

    42.4M *42=17.8 billion...

    Good Luck to all and do your due diligence always...
  • A
    I fail to see how rising bond yields or flailing stimulus or poor retail numbers should be affecting the number of people being treated for DVT or PE... why is this stock not a safe haven? it seems to be at the whim of all other market winds.
  • A
    here comes the BOOM!
    couldn't find the Kevin James gif, but would've been appropriate...
  • A
    revenue growing triple digits, topped the range of expectations, 2.5x YoY.
    increased margins
    increased guidance outlook
    FDA approval granted on new product

    ... I'll hold. I know it shouldn't be a CPI dependent stock, but the way i've been timing sales and buys, i'll just hold this one for a while...
  • b
    Don’t really get this technology! I manage close to 200 patients weekly to prevent DVT.
  • D
    Numbers are very good, future is even better......
  • S
    CEO on the most recent conference call: “the operating environment is considerably improved since Q4 and probably even since our last earnings call, which was not so long ago (2 months) ….and so I don’t think there is any COVID related headwinds to bringing on new customers.” AND they raised guidance for the year!
  • A
    After listening to the Healthcare Conference posted on Feb. 24th, a few takeaways I got out of it:
    5% of eligible patients were treated for DVT which leaves huge "marketshare" gains to be had. No debt, already profitable, working on educating and opening treatment centers and already showing YoY multiples of revenue. Reminds me of DXCM from 4-5 years ago, where they are first to market and leaders in treatment leading to multiples of growth as adoption of their product is realized. Just started and not tapped any international sales; a whole new market to be tapped, first concentrating on western Europe. Fingers crossed, I just can't help thinking this stock will explode and show multiples of returns for at least the next 3 years.